(NASDAQ: AYTU) Aytu Biopharma's forecast annual revenue growth rate of 10.52% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 363.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 56.5%.
Aytu Biopharma's revenue in 2026 is $63,696,000.On average, 5 Wall Street analysts forecast AYTU's revenue for 2026 to be $574,288,909, with the lowest AYTU revenue forecast at $520,811,005, and the highest AYTU revenue forecast at $652,554,722. On average, 5 Wall Street analysts forecast AYTU's revenue for 2027 to be $846,028,792, with the lowest AYTU revenue forecast at $699,644,620, and the highest AYTU revenue forecast at $1,093,296,600.
In 2028, AYTU is forecast to generate $940,076,140 in revenue, with the lowest revenue forecast at $903,215,204 and the highest revenue forecast at $967,726,937.